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WDR5 supports colon cancer cells by
promoting methylation of H3K4 and
suppressing DNA damage
Beth K. Neilsen1, Binita Chakraborty1,4, Jamie L. McCall1,5, Danielle E. Frodyma1, Richard L. Sleightholm2,
Kurt W. Fisher1,3 and Robert E. Lewis1*

Abstract
Background: KMT2/MLL proteins are commonly overexpressed or mutated in cancer and have been shown to
support cancer maintenance. These proteins are responsible for methylating histone 3 at lysine 4 and promoting
transcription and DNA synthesis; however, they are inactive outside of a multi-protein complex that requires WDR5.
WDR5 has been implicated in cancer for its role in the COMPASS complex and its interaction with Myc; however,
the role of WDR5 in colon cancer has not yet been elucidated.
Methods: WDR5 expression was evaluated using RT-qPCR and western blot analysis. Cell viability and colony
forming assays were utilized to evaluate the effects of WDR5 depletion or inhibition in colon cancer cells.
Downstream effects of WDR5 depletion and inhibition were observed by western blot.
Results: WDR5 is overexpressed in colon tumors and colon cancer cell lines at the mRNA and protein level. WDR5
depletion reduces cell viability in HCT116, LoVo, RKO, HCT15, SW480, SW620, and T84 colon cancer cells. Inhibition
of the WDR5:KMT2/MLL interaction using OICR-9429 reduces cell viability in the same panel of cell lines albeit not
to the same extent as RNAi-mediated WDR5 depletion. WDR5 depletion reduced H3K4Me3 and increased phosphorylation
of H2AX in HCT116, SW620, and RKO colon cancer cells; however, OICR-9429 treatment did not recapitulate these effects in
all cell lines potentially explaining the reduced toxicity of OICR-9429 treatment as compared to WDR5 depletion. WDR5
depletion also sensitized colon cancer cells to radiation-induced DNA damage.
Conclusions: These data demonstrate a clear role for WDR5 in colon cancer and future studies should examine its
potential to serve as a therapeutic target in cancer. Additional studies are needed to fully elucidate if the requirement for
WDR5 is independent of or consistent with its role within the COMPASS complex. OICR-9429 treatment was particularly
toxic to SW620 and T84 colon cancer cells, two cell lines without mutations in WDR5 and KMT2/MLL proteins suggesting
COMPASS complex inhibition may be particularly effective in tumors lacking KMT2 mutations. Additionally, the ability of
WDR5 depletion to amplify the toxic effects of radiation presents the possibility of targeting WDR5 to sensitize cells to
DNA-damaging therapies.
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Background
Recent technological advances and significant efforts to
identify genetic alterations in cancer demonstrate that the
KMT2/MLL proteins are commonly altered in multiple
cancers. While it is well-established that KMT2A/MLL1 is
commonly involved in pro-tumorigenic chromosomal
translocations or rearrangement in leukemia [1], the frequency of KMT2/MLL genetic alterations and overexpression in other tumor types, including breast, prostate,
pancreas, stomach, and colon, was surprising.
The KMT2/MLL family of proteins includes KMT2A/
MLL1, KMT2B/MLL2 or MLL4, KMT2C/MLL3,
KMT2D/MLL4 or MLL2, KMT2F/SETD1A, and
KMT2G/SETD1B. KMT2/MLL family proteins, while
highly related, have both distinct and redundant functions
[2]. In general, the KMT2/MLL proteins are the major
components of the SET/MLL COMplex of Proteins Associated with Set1 (COMPASS) complex in humans that is
responsible for mono-, di-, and tri- methylating histone
H3 at lysine 4 (H3K4). In humans, the KMT2/MLL proteins have little methylation activity outside of the SET/
MLL COMPASS complex, which consists of one of the
KMT2/MLL proteins (MLL1, MLL2, MLL3, MLL4,
SETD1A, or SETD1B) in addition to a common subcomplex that includes WDR5, RBBP5, ASH2L, DPY30
(WRAD subcomplex) [3].
The formation of this complex stimulates the KMT2/
MLL activity by increasing H3K4 affinity [4]. The
addition of methyl groups to H3K4 generally promotes
transcription by recruiting transcription factors and
coactivators to promoters while also interfering with the
addition of epigenetic modifications that repress transcription [4]. However, the location of methylation (in
promoters or enhancers) and degree of methylation
(mono-, di-, and tri-methylation) varies between KMT2/
MLL proteins and can be tissue-specific.
Recent studies have identified a correlation between
H3K4Me3 enrichment and transcriptional fidelity as well
as enhanced elongation rates [5, 6] suggesting a potential
role for the COMPASS complex in promoting DNA synthesis and preventing DNA damage during replication
thereby supporting cancer cell proliferation. MLL1 and
WDR5 have been shown to be required for proper
chromosome congression and spindle assembly during
mitosis, which may affect chromosomal stability [7].
Additionally, mutations in MLL2 have been shown to
cause genome instability [8]. In another report, AML
driven by KMT2A/MLL1 fusions were shown to be
proficient in DNA damage response (DDR) leading to
resistance to PARP inhibitors. However, depleting, or
inhibiting cells of the KMT2A/MLL1 downstream target
HOXA9 caused DDR impairment and PARP inhibitor
sensitization [9]. Together these data suggest a role for
this complex in supporting DNA replication and
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maintaining DNA fidelity, thereby promoting cancer cell
survival and proliferation. Consistent with this proposed
role by which WDR5 may support tumor growth and
survival, depletion of KMT2D in multiple pancreatic
cancer cell lines increased their responsiveness to 5-FU
[10] suggesting the possibility that KMT2/MLL inhibitors could be used for chemotherapy or radiation
sensitization.
Within cancer, the COMPASS complex has been
shown to promote transcriptional reprogramming
through increased methylation at H3K4 [11] and by
interacting with commonly recognized oncogenic transcription factors. Specific targets of KMT2/MLL epigenetic regulation have been shown to include hTERT
(KMT2A, in melanoma) [12], several HOX genes
(KMT2A) [9], ERalpha target genes in breast cancer
(KMT2D) [13, 14], and androgen receptor target genes
in prostate cancer (MLL1 and WDR5) [15]. Specifically,
KMT2C and KMT2D depletion caused downregulation
of genes related to cell-cycle and proliferation based on
microarray and gene-set enrichment analysis [10]. In
these reports, inhibition or depletion of key KMT2/MLL
components decreased the expression of important transcriptional targets thereby inhibiting cancer cell growth
[13, 16]. In colon cancer, KMT2D and KMT2C
mutations are common and are present in 10% of tumors (Table 1, COSMIC v83). In contrast, the common
components of the COMPASS complex were rarely mutated (Table 1). Additionally, many of the commonly
used colon cancer cell lines harbor multiple mutations
within KMT2/MLL family members (Additional file 1:
Table S1, COSMIC Cell Lines Project, [17]). The effects
of these mutations are still being debated, but are likely
pro-tumorigenic. One study demonstrated that KMT2D
promoted global H3K4 monomethylation in transcriptional enhancers, and depletion of KMT2D in two colon
Table 1 Percent of samples with mutated COMPASS complex
proteins (COSMIC v83)
Frequency of Mutations in Colon Adenocarcinoma
Gene

Percent
Mutated

Samples
(Mutated/Tested)

KMT2C/MLL3

13%

323/2478

KMT2D/MLL2

11%

243/2209

KMT2A/MLL

7%

152/2178

KMT2B/MLL4

7%

150/2130

KMT2F/SETD1A

6%

116/2109

KMT2G/SETD1B

3%

67/2098

RBBP5

2%

32/2109

WDR5

1%

28/2109

ASH2L

1%

25/2109

DPY30

< 1%

6/2098
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cancer cell lines (HCT116 and DLD-1) decreased cancer
cell proliferation and migration [11].
Based on the significant requirement for the WRAD
subcomplex for activity of all KMT2/MLL proteins and
the emerging evidence that KMT2/MLL proteins likely
play a role in tumor maintenance, evaluating the efficacy
of targeting components of the WRAD subcomplex for
the treatment of cancer could be highly efficacious.
In this report, we show that WDR5, a common component of the SET/MLL COMPASS complex, is overexpressed in human colon cancer tumors and cell lines
and is required for colon tumor cell proliferation.
WDR5 depletion decreased H3K4Me3 and increased
DNA damage as measured by increased H2AX phosphorylation. WDR5 depletion sensitized cells to ionizing
radiation further as the combination increased DNA
damage and PARP cleavage. Further, we show that
OICR-9429, an inhibitor of the interaction between
KMT2/MLL and WDR5, is required for colon cancer
growth. Thus, these data demonstrate a previously
unrecognized role for WDR5 in colon cancer cell proliferation and survival.

Methods
Cell culture

Colon cancer cell lines HCT116 (ATCC CCL-247), LoVo
(ATCC CCL-229), RKO (CRL-2577), HCT15 (ATCC
CCL-225), SW480 (ATCC CCL-228), SW620 (ATCC
CCL-227), and T84 (ATCC CCL-248) were obtained from
American Type Culture Collection (ATCC). Cells were
grown in Dulbecco’s Modified Eagle’s Medium (DMEM)
with 10% fetal bovine serum (FBS). All colon cancer cells
were grown with ambient O2 and 5% CO2 at 37 °C. Immortalized, non-transformed human colonic epithelial cell lines
(HCEC) were kindly provided by Jerry Shay (UT Southwestern) [18]. HCEC media consists of four parts DMEM
to one-part media 199 (Sigma-Aldrich) supplemented with
1 μg/mL hydrocortisone, 25 ng/mL EGF, 10 μg/mL insulin,
5 nM sodium selenite, 2 μg/mL transferrin and 2% cosmic
calf serum (GE Healthcare). HCECs were grown in 2% O2
and 5% CO2 at 37 °C within an enclosed hypoxia chamber.
HCECs are grown on Corning™, Primaria™ plates.
siRNA transfections

Pooled or individual ON-TARGET plus siRNAs targeting
WDR5 (L-013383-00-0005) or a non-targeting siRNA
control (D-001810-01) (Dharmacon), were transfected
into the cell lines listed above using the Lipofectamine
RNAiMAX (Invitrogen) reverse transfection protocol and
as described following: 5 μL of RNAiMax, 2 mL of media
(150,000 cells/mL), 500 μL Opti-MEM media, and 40 nM
RNAi were combined in 6-well plates. The same reverse
transfection protocol was utilized for HCEC transfections
with the following reagent quantities: 5 μL RNAiMax
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transfection reagent per 5 mL of media and 100,000 cells/
mL with an RNAi concentration of 20 nM in 6-well plates.
RIPA lysis buffer with protease and phosphatase inhibitors
was used to lyse cells 72 h after transfected unless otherwise noted. siRNA sequences can be found in Additional
file 1: Table S2.
Propidium iodide (PI) stain cell cycle analysis

The sub-G1 peak was measured following propidium
iodide (PI) staining to assess cell apoptosis. All adherent
and nonadherent cells were collected and placed in
round bottom 12 × 75 mm polystyrene tubes (BD Falcon,
352,054). Centrifugation for 3 min at 2800 RPM using
an Immunofuge II was completed to pellet the cells. The
media was aspirated, and the cells were resuspended in
PBS. Cells were again pelleted by centrifugation for
3 min at 2800 RPM using an Immunofuge II. The PBS
was aspirated, and the cells were fixed in 1 mL of ice
cold 70% ethanol overnight at − 20 °C. Cells were
warmed to room temperature, pelleted by centrifugation,
then rehydrated in room temperature PBS and incubated
for 15 min at 37 °C. Centrifugation was utilized to pellet
the cells, PBS was aspirated, and the cells were resuspended in PI stain for 8–15 h (overnight). PI staining
was evaluated using an LSR II flow cytometer and analyzed using FlowJo Cell Cycle analysis.
Annexin V/Propidium iodide (PI) apoptosis analysis

Cells were assayed for apoptosis based on Annexin V/PI
staining using an Invitrogen FITC Annexin V/Dead Cell
Apoptosis Kit (V13242) following the manufacturer’s
instructions. All nonadherent and adherent cells were
collected in a 15 mL conical. Centrifugation was used to
pellet the cells. The media was aspirated, cells were resuspended in PBS, and counted using a hemocytometer.
200,000 cells were placed in a 12 × 75 mm round bottom
polystyrene tube (BD Falcon, 352,054) and again centrifuged to pellet the cells. The PBS was aspirated, and the
cells were resuspended in 100 μL of 1X Binding buffer at
a concentration of 2 million cells/mL (200,000 cells in
100 μL of 1X Binding buffer). 5 μL of Annexin V solution
and 1 μL of PI were added to each sample and allowed to
incubate for 15 min. Then 400 μL of 1X Binding buffer
was added and samples were put on ice. Staining was evaluated using a Becton-Dickinson LSR II flow cytometer
immediately after staining. Results were analyzed using
FlowJo software to determine the percentage of cells that
stained with Annexin V (early apoptosis), PI (late
apoptosis), or both (necrosis).
Radiation treatment

200,000 cells/well were transfected on 6-well plates.
Transfections were done as described above. At 48 h, 3
Gray of ionizing radiation was applied to the cells in a
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single dose (RS-2000 Irradiator). At 96 h after plating,
cells were collected for western blot analysis.
Reagents

OICR-9429 was purchased from Caymen Chemical
(1801787–56-3). DMSO was purchased from Fisher
(D128–500). OICR-9429 was dissolved in DMSO at a
stock concentration of 10 mM. Stock OICR-9429
(10 mM) or DMSO was dissolved in pre-warmed media
at a 1:1000 ratio to achieve a final drug concentration of
0.1% DMSO or 10 μM of OICR-9429 for drug treatments [19].
Cell growth assay

5000–10,000 (HCEC, LoVo, T84) cells/well were transfected or plated on white or clear 96-well plates. Reverse
transfections followed the same protocol as previously
described but were completed using a 1:25 ratio for all
the reagents (20 μL of the final mixture added to each
well). At 48, 72, or 96 (start with half as many cells)
hours post-transfection or drug treatment, alamarBlue®
(ThermoFisher Scientific) was added at a ratio of 100 μL
per 1 mL of media to each well. Plates were incubated at
37 °C for 1–3 h and fluorescence was measured
(POLARstar OPTIMA). Results were background
subtracted (well with media + alamarBlue® without any
cells) and normalized with the control being set to 1. In
other instances, cell viability was measured using the
manufacturers’ protocol with the CellTiter-Glo® Luminescent Cell Viability Assay (Promega). Based on this
protocol, 90 μl of CellTiter-Glo® reagent was added to
each well, cells were then shaken for two minutes, and
incubated for 10 min at room temperature to stabilize
the signal. The luminescence was measured using a
POLARstar OPTIMA. Note: CellTiter-Glo® must be
completed on plates with opaque side walls.
Western blot analyses

Radioimmunoprecipitation assay (RIPA) buffer (50 mM
Tris-HCl, 1% NP-40, 0.5% Na deoxycholate, 0.1% Na dodecyl sulfate, 150 mM NaCl, 0.5 mM Na3VO4, 2 mM
EDTA, 2 mM EGTA, 10 mM NaF, 10 μg/mL aprotinin,
20 mM leupeptin, 2 mM PMSF) was used to prepare
whole cell lysate from collected cells. Promega BCA protein assay was utilized to evaluate protein concentration.
SDS-PAGE gel electrophoresis was completed, proteins
were transferred to nitrocellulose membranes, membranes were blocked for 45 min in PBS-based blocking
buffer (LI-COR Biosciences, 927–40,000), and incubated
in primary antibody (listed below) at 4 °C overnight. Secondary antibodies (LICOR IRDye 680LT and 800CW)
were diluted 1:10,000 in 0.1% TBS-Tween. The LI-COR
Odyssey was used to image the western blots.
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Antibodies

Primary antibodies (catalog numbers) and dilutions were
as follows:
WDR5 (ab22512, Abcam) 1:1000; α-tubulin (B-5-1-2,
Santa Cruz) 1:2500; PARP (9542, Cell Signaling) 1:1000;
Phospho-Histone H2A.X (Ser139)(2577, Cell Signaling);
H2A.X (2595, Cell Signaling); H3K4Me3 (ab8580,
Abcam) 1:1000; H3K4Me1 (ab8895, Abcam) 1:1000;
Histone 3 (ab1791, Abcam) 1:2500; and p53 (6243, Santa
Cruz) 1:1000.
RT-qPCR

1 mL TriReagent (MRC, TR118) was used to collect
RNA, which was then stored at − 80°C until extraction.
The manufacturer’s protocol was followed for RNA
extraction. A NanoDrop 2000 (Thermo Scientific) was
used to quantify the RNA. Following the manufacturer’s
protocols, reverse transcription was completed using
iScript™ Reverse Transcription Supermix (Bio-Rad, 170–
8840) with 1 μg of total RNA in 20 μL reaction volume.
Amplification and quantification was performed using
the SsoAdvanced™ Universal SYBR Green Supermix
(Bio-Rad). Primer sequences and reaction conditions for
RT-qPCR are listed in Additional file 1: Table S3.
TCGA.
The FPKM-UQ normalized RNASeq values of primary
tumors (n = 478 with 456 unique patients) and normal
solid tissue (n = 41) samples from within The Cancer
Genome Atlas (TCGA) Colon Adenocarcinoma (COAD)
dataset was used to evaluated mRNA expression. Results
were analyzed for statistical significance using an unpaired Student’s t tests.
Statistical analyses

Prism Software (GraphPad, La Jolla, CA) was used to
calculate P and EC50 values. P values of less than or
equal to 0.05 were considered statistically significant.
Significance of qPCR results was evaluated using
one-way ANOVA with Dunnett’s post-test to individually compare all cell lines to the control cell line HCEC
(Fig. 1b). The TCGA COAD RNASeq FPKM-UQ expression, cell viability assays, colony number and size,
Annexin V/PI apoptotic assay (early and late apoptosis),
and Propidium Iodide cell cycle analysis (sub-G1 peak
and G1 phase) were statistically evaluated using an unpaired, two-sided t-test for each target (Fig. 1a), cell line
analyzed (Figs. 2 and 3b), and treatment (Fig. 4b). Data
are shown as mean +/− standard deviation (SD) unless
otherwise noted.

Results
WDR5 is overexpressed in colon cancer cells

To evaluate the expression of the components of the
WRAD subcomplex in cancer, the mRNA levels of
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a

b

c

Fig. 1 WDR5 is overexpressed in colon cancer cells. a WDR5, RBBP5, ASH2L, and DPY30 gene expression (RNASeq) data from the Colon
Adenocarcinoma (COAD) dataset within TCGA for unpaired primary colon tumors and normal solid tissue samples. Tumor includes 478 samples
from 456 patients for each gene. Normal includes 41 samples from 41 patients for each gene. For each boxplot the middle line represents the
median, the box represents the 25th to 75th percentile and the whiskers represent the 5th to 95th percentile. The results published here are in
whole or part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. b RT-qPCR and (c) western blot of
WDR5 in a panel of colon tumor cell lines as compared to immortalized, non-transformed HCECs. RT-qPCR data are shown as mean ± SD.
** p < 0.01 *** p < 0.001 **** p < 0.0001

WDR5, RBBP5, ASH2L, and DPY30 in tumors compared to normal solid tissue samples were examined
based on RNASeq analysis from the colon adenocarcinoma (COAD) dataset within The Cancer Genome Atlas
(Fig. 1a). WDR5, RBBP5, and DPY30 are increased in tumors relative to normal tissue; however, WDR5 is
expressed at the highest level and shows the most dramatic increase in expression between normal tissue and
colon tumor tissue so it was selected for further study.
WDR5 is also overexpressed at the mRNA (Fig. 1b) and
protein level (Fig. 1c) in a panel of colon cancer cells as
compared to immortalized, yet non-transformed human
colon epithelial cells (HCECs) [18] suggesting WDR5
may play a pro-tumorigenic role in colon cancer.
Validation of four siRNAs targeting WDR5

To evaluate the importance of WDR5 in colorectal
cancer, cell viability following RNAi-mediated WDR5
depletion was measured. However, prior to performing
this analysis, the individual siRNA oligos targeting
WDR5 were validated. Evaluation of the individual oligos
from the SMARTpool (Dharmacon) of four oligos targeting WDR5 revealed that all four dramatically

decreased WDR5 levels. However, in HCT116 cells,
oligo #6, the SMARTpool (a pre-mixed pool of all four
oligos), and 1:1:1:1 pool of all four oligos dramatically
decreased viability to a level substantially lower than the
other three individual oligos (#5, #7, and #8) even
though the levels of WDR5 depletion were comparable
(Additional file 1: Figure S1A). Visually, oligo #6 and
pools containing all four oligos induced substantial cell
death and cell non-adherence, whereas oligos #5, #7,
and #8 appeared to reduce proliferation and induced a
lower level of cell death. Examining the mechanism further, multiple oligos induced DNA damage, as evidenced
by increased phosphorylation of H2AX (γH2AX), but
only oligo #6 increased p53 expression and induced
PARP cleavage in HCT116 cells (Additional file 1: Figure
S1B). This observation suggested an additional off-target
effect for oligo #6 distinct from its ability to suppress
the expression of WDR5. A blast search using the oligo
#6 sequence demonstrated a 100% match to WDR5, but
also shared a high degree of similarity to ME1 sharing a
14-nucleotide substring within the 19-nucleotide siRNA
oligo (Additional file 1: Figure S1C). Previously, ME1 depletion was shown to induce p53 expression [20],
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a

b

c

Fig. 2 WDR5 depletion or disruption of the COMPASS complex limits cell proliferation or viability in colon cancer cells. a and b Cell viability in a
panel of colon cancer cells as compared to HCECs following RNAi-mediated depletion of WDR5. Viability was measured by CellTiter-Glo® (a) and
alamarBlue® (b) assays 72 h after transfection. c Cell viability in a panel of colon cancer cells as compared to HCECs following 72-h treatment with
10 μM OICR-9429 as measured by alamarBlue®. Data are shown as relative light units or relative fluorescent intensity ± SD. ** p < 0.01 ***
p < 0.001 **** p < 0.0001

suggesting this off-target effect could cause p53 induction in HCT116 cells. Reassuringly, all four individual oligos and both pools reduced HCT116
viability as measured by alamarBlue® following WDR5
depletion by more than 30% in 72 h suggesting
WDR5 itself is playing a role supporting colon cancer
cells. However, to avoid the possibility of confounding
off-target effects and non-specific p53 induction, oligo
#6 was excluded from the oligo pools in subsequent
experiments.

WDR5 is required for cancer cell survival

The importance of WDR5 in colorectal cancer is suggested by its selective upregulation in colon tumor cells
and tissues compared to normal colonic epithelium. To
determine whether WDR5 is required for colon cancer
cell survival, cell viability in colon cancer cell lines and
HCECs following transient WDR5 depletion by RNAi
was measured. Cell viability was measured using
CellTiter-Glo® Luminescent Cell Viability Assay 72 h
after WDR5 depletion. WDR5 depletion reduced cell
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b

Fig. 3 Disruption of the COMPASS complex decreases cell colonies in colon cancer cells. a and b Representative pictures (a) and quantification of
number and average size of colonies (b) formed on 24-well plates in colon cancer cell lines following treatment with OICR-9429 treatment for
10–14 days. Number of colonies and average colony size are shown as mean ± SD. * p < 0.05 ** p < 0.01 *** p < 0.001

ATP levels by 15–30% in six colon cancer cell lines
(Fig. 2a). These results were largely confirmed using the
alamarBlue® Cell Viability Assay after 96 h of WDR5
depletion (Fig. 2b) with the only change being WDR5
depletion having no effect on viability in LoVo cells as
measured by alamarBlue®. In contrast to the colon cancer cell lines, following WDR5 depletion HCECs demonstrated only a 5% decrease in cell ATP levels (Fig. 2a)
and no difference in viability as measured by the alamarBlue® assay (Fig. 2b).
To evaluate the effect of WDR5 inhibition, the effect of OICR-9429 treatment on colon cancer cells
and HCECs was examined. OICR-9429 is an

antagonist of the interaction of WDR5 with peptide
regions of KMT2/MLL and Histone 3, and disrupts
COMPASS complex formation by blocking the
interaction between WDR5, KMT2/MLL, and RBBP5
[19, 21]. Previous reports have also demonstrated
that treatment with 10 μM OICR-9429 disrupted the
interaction of WDR5 with MLL1 or RBBP5 to less
than 20% based on co-immunoprecipitation experiments, and treatment with 5–20 μM OICR-9429 dramatically decreased cell viability in in vitro models
of AML [19]. The effect of OICR-9429 on HCT116
colon cancer cells was evaluated by performing a
dose response curve based on cell viability as
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a

b

Fig. 4 WDR5 depletion increases DNA damage and reduces H3K4Me3. a Western blot of PARP, γH2AX, total H2AX, H3K4Me3, and H3K4Me1
following 96-h WDR5 knockdown or 72-h OICR-9429 treatment in colon cancer cells. b Percentage of cells within the sub-G1, G1, S, or G2 phase
based on propidium iodide staining and flow cytometry analysis following WDR5 depletion for 72 h or 10 μM OICR-9429 treatment for 48 h in
three colon cancer cell lines

measured with alamarBlue® following treatment with
OICR-9429 for 48 h with doses ranging from 10 nM
to 100 μM (Additional file 1: Figure S2) which revealed that 10 μM OICR-9429 substantially decreased cell viability. Therefore, based on previous
reports demonstrating substantial interference in
COMPASS complex formation and the drug dose response curve results, a dose of 10 μM was selected
for future studies.
Treatment with 10 μM OICR-9429 for 72 h also decreased cell viability (alamarBlue® Cell Viability Assay),
but to a lesser extent than seen with WDR5 depletion in
some colon cancer cell lines (Fig. 2c). Interestingly,
OICR-9429 treatment had less of an effect in RKO and
HCT116 cells, two cell lines that harbor WDR5 mutations that may reduce the affinity of OICR-9429 for
WDR5. Two cell lines with wildtype WDR5 and relatively few or no mutations in other COMPASS components (Additional file 1: Table S1), SW620 and T84 cells,
were more sensitive to both WDR5 depletion as well as
OICR-9429 treatment with approximately a 50% decrease in cell viability over 72 h.

OICR-9429 treatment dramatically decreases colony
growth in colon cancer cell lines

Based on the known contribution of WDR5 to the
COMPASS complex that methylates lysine 4 on histone
3 (H3K4), we hypothesized that the effects of WDR5 depletion or OICR-9429 treatment will be enhanced over
time. Therefore, the effect of OICR-9429 on colony
growth of colon cancer cell lines was examined (Fig. 3a).
OICR-9429 treatment decreased the number of colonies
in RKO, T84, SW480, and SW620 cells, with a downward trend seen in LoVo cells (Fig. 3b). Additionally,
colony size was decreased in T84, SW620, and HCT116
cells, while RKO and LoVo cells trended downwards
(Fig. 3b).
WDR5 depletion increases DNA damage and decreases
trimethylation of H3K4

To further examine the role WDR5 plays in cancer, the
effect of WDR5 depletion (oligos #7 and #8 only) and
OICR-9429 treatment on H3K4Me3, H3K4Me1, and
phosphorylation of H2AX (γH2AX) was examined in
HCT116, SW620, and RKO cells. These cell lines were
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chosen because HCT116 cells were highly sensitive to
WDR5 depletion, but much less so to OICR-9429 treatment; RKO cells were sensitive to both WDR5 depletion
and OICR-9429 treatment, but to a lesser extent overall;
and SW620 cells were highly sensitive to both WDR5
depletion and OICR-9429 treatment based on the cell
viability assays (Fig. 2). In all three cell lines, WDR5 depletion induced γH2AX formation and decreased
H3K4Me3 (Fig. 4a). In SW620 cells, WDR5 depletion
also decreased H3K4Me1 (Fig. 4a). OICR-9429 treatment induced γH2AX in SW620 cells, but did not affect
γH2AX in the other two cell lines (Fig. 4a). OICR-9429
treatment decreased H3K4Me3 levels in HCT116 cells
and to a lesser extent in RKO and SW620 cells (Fig. 4a).
To evaluate the ability of WDR5 depletion or
OICR-9429 treatment to induce apoptosis or affect cell
cycle, Annexin V/Propidium Iodide (PI) Apoptosis staining and Propidium Iodide (PI) Cell Cycle analyses were
completed and analyzed by flow cytometry. In HCT116
cells, WDR5 depletion (oligos #5, #7, and #8) for 72 h
caused a robust induction of apoptosis as evidenced by a
significant increase in cells in early apoptosis following
Annexin V/PI staining (Additional file 1: Figure S4) and
sub-G1 peak following PI cell cycle analysis (Fig. 4b,
Additional file 1: Figure S3). Treatment with 10 μM
OICR-9429 for 48 h also increased the percentage of
HCT116 cells in late apoptosis (Additional file 1: Figure
S4); however, OICR-9429 treatment induced apoptosis to
a lesser extent than WDR5 depletion (Fig. 4b, Additional
file 1: Figure S4). This is consistent with the effect of these
two treatments on cell viability that demonstrated a substantial decrease in viability following WDR5 depletion
and smaller effect of OICR-9429 treatment in HCT116
cells (Fig. 2). In SW620 cells, there were only slight increases in early apoptotic cells (Additional file 1: Figure
S4), but the percentage of cells within the G1 phase was
substantially increased for both WDR5 depletion (oligos
#5, #7, and #8) for 72 h or 10 μM OICR-9429 treatment
for 48 h (Fig. 4b, Additional file 1: Figure S3). This is consistent with the viability data in SW620 cells (Fig. 2),
which demonstrated a consistent robust decrease of cell
viability or cell number following WDR5 depletion or
OICR-9429 treatment. RKO cells demonstrated a minor
detrimental effect on viability following either WDR5 depletion (oligos #5, #7, and #8) for 72 h or 10 μM
OICR-9429 treatment for 48 h based on only a small increase in the fraction of early apoptotic cells (Additional
file 1: Figure S4). In RKO cells, cell cycle analysis also revealed a small increase in the percentage of cells within
the G1 phase particularly with WDR5 depletion (Fig. 4b,
Additional file 1: Figure S3).
These results suggest that WDR5 depletion induces
DNA damage in colon cancer, but the OICR-9429 treatment is unable to fully replicate this effect in HCT116
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and RKO colon cancer cells. This could be due to the
presence of WDR5 mutations in these cell lines that
render them less sensitive to OICR-9429 treatment. In
contrast, SW620 cells that harbor wildtype WDR5 appear to be equally sensitive to WDR5 RNAi-mediated
depletion and OICR-9429 treatment and demonstrate
increased γH2AX with either manipulation. The effect
on H3K4 methylation appears to be more consistently
affected by OICR-9429 treatment. This could be due to
the drug’s ability to inhibit the COMPSS complex independent of WDR5. This raises a question as to whether
the effect of WDR5 on γH2AX is a function of its role
within the COMPASS complex or another mechanism.
In fact, RBBP5 depletion did not affect cell viability
suggesting that WDR5 may function outside of the
COMPASS complex to promote tumorigenesis
(Additional file 1: Figure S5).
WDR5 depletion sensitizes colon cancer cells to radiationinduced DNA damage

To evaluate the extent to which loss of WDR5 sensitizes
cells to DNA damage, the effect of WDR5 depletion (oligos #7 and #8 only) on radiation-induced γH2AX formation and PARP cleavage was assessed. HCT116, SW620,
and RKO cells were depleted of WDR5 for 48 h prior to
irradiation. Cells were allowed to recover for 48 h before
collection. In cells transfected with a non-targeting
siRNA, irradiation increased γH2AX levels. This
radiation-induced increase in γH2AX levels was further
amplified with the loss of WDR5. SW620 and RKO cells
demonstrated a step-wise increase in γH2AX levels with
WDR5 depletion and irradiation with maximal γH2AX
in the cells that received irradiation in conjunction with
WDR5 depletion (Fig. 5). In contrast, HCT116 cells
demonstrated a substantial increase in γH2AX with
WDR5 depletion regardless of the addition of radiation
(Fig. 5). This could be a consequence of the high level of
endogenous genomic instability in HCT116 cells. Regardless, in all conditions, WDR5 depletion increased
γH2AX levels that indicate increased DNA damage.

Discussion
WDR5 functions to serve as a core component of several
complexes within the cell [22]. It has been studied most for
its role in the SET/MLL COMPASS complex, which
mono-, di-, and tri-methylates histone 3 lysine 4
(H3K4Me1–3) [23–25]. WDR5 has also been shown to
contribute to specific recognition of H3K4Me3 targets [26]
contributing to increased transcription of target genes as
H3K4 methylation often occurs within enhancer or
promoter regions depending on the KMT2/MLL protein
included in the complex. As part of the COMPASS
complex, WDR5 has a significant role in development as it
regulates embryonic stem cell pluripotency, self-renewal,
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Fig. 5 WDR5 depletion increases sensitivity to irradiation. Western blot of γH2AX and PARP following 96-h WDR5 knockdown with the addition of
a single dose of 3 Gray ionizing radiation 48 h prior to collection

and transcriptional reprogramming. The developmental
effects of WDR5 are largely a consequence of its ability to
modulate transcription of specific targets, including multiple HOX genes and SOX9 [27–30] that promote stem
cell-like states by promoting the maintenance of active
chromatin for pluripotency genes [28, 31–34].
WDR5 has also been shown to promote its own
expression through a positive feedback loop where increased H3K4Me3 at the WDR5 promoter increases its
transcription [30]. This positive feedback loop could be
contributing to the consistent overexpression of WDR5
demonstrated here in both colon cancer cell lines as well
as human colon tumors; however, this is difficult to
definitively demonstrate experimentally. The overexpression of WDR5 is not unique to colon cancer as recent
studies have demonstrated WDR5 is overexpressed in
several cancer types including breast, prostate, bladder,
and pancreatic cancer. WDR5 overexpression has been
clinically associated with worse patient outcomes in
breast cancer and hepatocellular carcinoma [35, 36].
Our data demonstrate that colon cancer cells rely on
WDR5 for increased proliferation and cell survival as depletion of WDR5 reduced cell viability. Other groups
have demonstrated similar findings and demonstrated
that WDR5 is required for cell survival and proliferation
in leukemia [37], prostate [15], bladder [38] breast [39],
and pancreatic cancer [40].
In general, the mechanism by which WDR5 supports
cancer cells has been shown to be through increased target
gene expression. For example, WDR5 has been shown to
promote EMT by promoting mesenchymal gene activation
[41] and binding to ZNF407 to promote colon cancer metastasis [42]. Depletion of WDR5 reduced ErbB2 expression

and cooperated with trastuzumab or chemotherapy to reduce ErbB2-positive breast cancer cell growth [39]. WDR5
has been shown to cooperate with HOTTIP to promote
HOXA9 in prostate and pancreatic cancer [43, 44] and
HOXA13 expression in esophageal and gastric cancer cells
by increasing H3K4Me3 on their promoters [45, 46]. In
bladder and gastric cancer, WDR5 increases the transcription of multiple cyclin proteins and stem
cell-associated genes via increased H3K4Me3 [35, 38,
47–49]. Our data demonstrate that this is also likely
the case in colon cancer cells, as WDR5 depletion
caused global H3K4Me3 levels to decrease, which is
believed to affect target gene transcription.
In conjunction with the findings that WDR5 is overexpressed and required in cancer, WDR5 has been shown
to physically interact with Myc and promote target recognition contributing to tumorigenesis [50–55]. Interestingly, a study using patient-derived xenografts of
pancreatic cancer demonstrated the WDR5:Myc interaction in vivo and showed this interaction prevented
DNA damage accumulation [55]. Two other reports
indicated that WDR5 regulated DNA replication and
chromosomal polyploidy [56] as well as regulated abscission through localization to the midbody [57].
Our data demonstrated that, in colon cancer, WDR5
depletion induced a robust increase in γH2AX levels
representative of an increase in DNA damage, which
suggests WDR5 is contributing to DNA fidelity possibly
through one of the previously described mechanisms.
The contribution of WDR5 to DNA fidelity may or may
not be independent of its role in the WRAD subcomplex
as RBBP5 did not affect viability in a panel of colon cancer cells. However, there are multiple reports suggesting
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that depletion of MLL1 and MLL2 induce DNA damage
as well as WDR5 suggesting a potential connection between the increased DNA damage following WDR5 depletion and its role in the COMPASS complex [5–10].
Resolution of γH2AX is thought to occur through exchange of γH2AX with dephosphorylated H2AX with
subsequent dephosphorylation of the released γH2AX by
phosphatases. One mechanism by which this occurs is
following H3K4 and H3K36 methylation by metnase, a
protein that contains a SET domain and is a potential
binding partner of WDR5 [58]. Metnase also promoted
non-homologous end-joining, restart of stalled replication forks, resolution of γH2AX, and knockdown increased sensitivity to ionizing radiation [58]. WDR5
itself has been shown to promote the incorporation of
H2AZ to promote global transcription [59] suggesting a
potential mechanism where WDR5 regulates cell cycle
progression through increased transcription (H2AZ incorporation) and release of cell cycle checkpoints (removal and dephosphorylation of γH2AX).
Our data demonstrated increased sensitivity to radiation, particularly in SW620 and RKO colon cancer
cells. While the HCT116 cells demonstrated increased
γH2AX following WDR5 depletion, WDR5 depletion
alone was sufficient to increase γH2AX to the same level
seen with the addition of radiation. Relative to the other
cell lines, HCT116 cells demonstrated the highest induction of γH2AX with WDR5 depletion alone. This could
be a result of the high level of genomic instability in
these cells. This, in combination with the additive effect
of WDR5 depletion following radiation-induced DNA
damage, suggests WDR5 is particularly required in cells
following DNA damage.
Overall, WDR5 depletion demonstrated a more robust
phenotype than OICR-9429 treatment. Several factors
could contribute to this disparity, but two likely possibilities are that either WDR5 plays a role independent of
the COMPASS complex that is not inhibited by
OICR-9429 treatment or mutations in WDR5 or other
COMPASS components limit the efficacy of OICR-9429.
Consistent with the second possibility, cells with limited
mutations in WDR5 and KMT2/MLL proteins had increased sensitivity to both WDR5 depletion and
OICR-9429. This could be because that without mutations in KMT2/MLL components, the KMT2/MLL proteins require COMPASS complex formation in order to
function to methylate H3K4 as they have very little enzymatic activity alone. Cells containing WDR5 mutations
could also be less sensitive to OICR-9429 as mutations
could reduce the affinity of the drug for WDR5. Additional studies on the effect of mutations in KMT2/MLL
proteins and WDR5 will provide further understanding
of the role of WDR5 and the COMPASS complex in
cancer. Further studies are also needed to fully
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distinguish if the role of WDR5 is a result of its
contribution to the COMPASS complex, is due to an alternative mechanism, or a combination of multiple
mechanisms.

Conclusions
This study demonstrated WDR5 is highly overexpressed
in colon cancer cells and is essential for colon cancer
cell viability. We further show that depletion of WDR5
sensitizes cells to irradiation. Together, these data demonstrate a clear role for this protein in colon cancer.
Treatment with OICR-9429 was particularly efficacious
in SW620 and T84 cells; however, in other colon cancer
cell lines, OICR-9429 was less effective than direct
RNAi-mediated depletion of WDR5. Interestingly, the
cells that were the most sensitive to OICR-9429 treatment had the fewest mutations in components of the
COMPASS complex, suggesting a potential role for
WDR5 inhibition particularly in tumors without KMT2/
MLL or WDR5 mutations.
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